Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBT-001
- Development stage
- Preclinical
- Lead developer
- Bambusa Therapeutics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Cell Therapies
- Administration
- Intravenous
01
Overview
BBT-001 is an experimental engineered B-cell immunotherapy being developed by Bespoke Biotherapeutics for the treatment of HER2-positive solid tumors. The therapy utilizes the company's proprietary NINJA (non-viral, large transgene, homology-mediated end-joining) platform, which employs CRISPR/Cas9 to precisely engineer B-cells to express anti-HER2 activity. These engineered B-cells are designed to function as 'cancer sentinels' that seek out and destroy residual and recurrent HER2-positive cancer cells. The program is currently in preclinical development and encompasses both autologous and allogeneic (off-the-shelf) product candidates.
- Other names
- HER2-targeted engineered B-cellHER-2-targeted engineered B-cellHER 2-targeted engineered B-cellB-cell immunotherapy
02
Targets
IL31 (IL-31)IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on BBT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBT-001.